Destiny Pharma announces positive results in XF-73 Dermal safety study from ongoing agreement with US Government’s NIAID
Brighton, United Kingdom, 1 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the successful completion of a preclinical safety study with a novel XF-73 dermal formulation.